Beyond Repair: An ACL Implant That Heals and Prevents Future Arthritis

WESTBOROUGH, MA – July 08, 2026 – The sharp pop, the immediate instability—a torn anterior cruciate ligament (ACL) has long been a dreaded, career-altering injury for athletes and active individuals. For decades, the solution was a compromise: reconstruction, a procedure that replaces the torn ligament with a tendon graft harvested from elsewhere in the body. While effective at restoring stability, this approach often sets a timer on a new problem: debilitating post-traumatic osteoarthritis (PTOA). Today, a paradigm shift is underway, moving from replacement to restoration, and new data suggests it may not only heal the knee but also protect its long-term health.

A Bridge to Natural Healing

Miach Orthopaedics, a Massachusetts-based company, is at the forefront of this shift with its Bridge-Enhanced ACL Restoration (BEAR®) Implant. Unlike traditional ACL reconstruction (ACLR), the BEAR procedure avoids removing the damaged ligament. Instead, it creates an environment for the body to heal its own tissue. The implant, a proprietary collagen scaffold, is placed between the torn ends of the ACL. A small amount of the patient’s own blood is injected into the implant, creating a rich, clot-like medium that stimulates the body's natural healing cascade.

This approach carries significant advantages. It eliminates the need for a second surgical site to harvest a graft, a process known to cause its own morbidity and lingering weakness. Studies have shown that patients receiving the BEAR Implant recover hamstring strength much faster than those undergoing ACLR with a hamstring graft—one study of collegiate athletes noted 98% hamstring strength recovery at 24 months, compared to just 63% for the reconstruction group. By preserving the original ligament tissue and its attachments, the procedure also holds the potential for more natural knee kinematics and better proprioception—the knee's innate sense of its position in space.

Evolving Techniques and Growing Evidence

At the recent American Orthopaedic Society for Sports Medicine (AOSSM) Annual Meeting, Miach Orthopaedics presented two-year outcomes from the first 200 patients in its Bridge Registry, a real-world study tracking the implant's performance. The findings highlight low ACL retear rates, trending with a previously published 5% rate for a smaller patient group.

Crucially, the data also suggests that outcomes are improving as surgeons gain more experience. “One of the most encouraging findings from the Bridge Registry is that refinements in BEAR Implant surgical technique can have a meaningful impact on patient outcomes,” said Dr. Jocelyn Wittstein, an orthopedic surgeon at Duke University and a study co-investigator. She noted that modified fixation and suture techniques were associated with a lower overall reoperation rate, giving surgeons greater confidence.

While the company is understandably protective of its proprietary methods, these "evolved techniques" likely involve nuanced adjustments to how the implant and bracing sutures are secured, optimizing the tension and stability needed to protect the delicate healing process. This commitment to iterative improvement is critical, as some earlier clinical trials noted higher failure rates for the BEAR Implant compared to the gold-standard ACLR. The new registry data, however, suggests that with refined techniques and proper patient selection, these risks are being mitigated, strengthening the case for restoration over reconstruction.

The Landmark Breakthrough: Halting Osteoarthritis

Perhaps the most profound implication of the BEAR Implant lies not in the immediate recovery, but in what it promises for the decades that follow. The specter of post-traumatic osteoarthritis looms large over every ACL injury, with some studies showing that up to 50% of individuals develop arthritis within 10 to 20 years of an ACLR procedure. This has long been considered an unfortunate, but unavoidable, consequence.

Earlier this year, in a move that could reshape the standard of care, the U.S. Food and Drug Administration (FDA) granted a label update for the BEAR Implant, making it the first and only sports medicine product with an FDA-cleared claim for reducing the risk of PTOA. The decision was based on powerful Level 1 clinical evidence from a six-year follow-up of patients from the pivotal BEAR I and BEAR II trials.

The results were striking: patients who underwent traditional ACL reconstruction had a PTOA rate six times higher than those treated with the BEAR Implant (33% vs. 5.7%). “For decades, the focus of ACL treatment has been on restoring stability, and many have thought that developing arthritis was an unavoidable tradeoff,” noted Dr. Gregory DiFelice, a strategic advisor to Miach. This data challenges that assumption, offering a path to not just stabilize the knee, but to preserve the joint itself.

From Niche Innovation to Mainstream Option

The combination of strong clinical data and a powerful long-term benefit is driving rapid adoption. What was once a niche procedure is quickly entering the mainstream, with nearly 10,000 patients now treated with the implant. This growth has been fueled by significant venture funding and a recent expansion of the FDA indication to include patients of any age, as well as those with partial tears.

“We are committed to advancing ACL restoration through continued innovation in surgical technique and a growing understanding of the importance of long-term knee health,” said Jamal Rushdy, president and CEO of Miach Orthopaedics. This commitment is crucial as the technology becomes more widely available.

While insurance coverage is becoming more common, it remains a hurdle for some, and not every patient is a candidate. The procedure is most effective when performed within 50 days of injury and requires a sufficient stump of the original ACL to remain. Furthermore, some surgeons remain cautious, preferring the long-established track record of ACLR, especially for elite, high-demand athletes. Yet, as real-world data from initiatives like the Bridge Registry continues to accumulate, the BEAR Implant is building an undeniable case. It represents a fundamental shift in medical philosophy—from replacing what’s broken to creating the conditions for the body to heal itself, potentially securing a healthier, more active future for countless patients.